Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Connie Kang. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Approval. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Donanemab (donanemab-azbt; KisunlaTM) is an amyloid β-directed antibody developed by Eli Lilly and Company for the treatment of Alzheimer's disease. Donanemab recently received approval in the USA for the treatment of adults with early symptomatic Alzheimer's disease (patients with mild cognitive impairment or mild dementia stage of disease). This article summarizes the milestones in the development of donanemab leading to this first approval for Alzheimer's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Zitieren
APA
Kang, C. (2024). Donanemab: First Approval. Drugs. https://doi.org/10.1007/s40265-024-02087-4
Vancouver
Kang C. Donanemab: First Approval. Drugs. 2024. doi:10.1007/s40265-024-02087-4
BibTeX
@article{Kang2024,
author = {Kang, Connie},
title = {Donanemab: First Approval},
journal = {Drugs},
year = {2024},
doi = {10.1007/s40265-024-02087-4}
}
EUVIMED